Lv1
86 积分 2022-10-26 加入
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
22天前
已完结
Cenerimod, a sphingosine-1-phosphate receptor modulator, versus placebo in patients with moderate-to-severe systemic lupus erythematosus (CARE): an international, double-blind, randomised, placebo-controlled, phase 2 trial
22天前
已完结
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled Trial
22天前
已完结
Safety and Efficacy of Long‐Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial
23天前
已完结
Trial of Anti-BDCA2 Antibody Litifilimab for Systemic Lupus Erythematosus
23天前
已完结
Trial of Anti-BDCA2 Antibody Litifilimab for Cutaneous Lupus Erythematosus
23天前
已完结
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
23天前
已完结
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment
23天前
已完结
PO:11:275 Safety and efficacy of subcutaneous ianalumab (VAY736) post-B cell recovery in patients with systemic lupus erythematosus: end of study results from a phase 2 study
23天前
已关闭
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
1个月前
已完结
皖公网安备34019202002308
